MedPlus Subsidiary Receives Drug License Suspension Orders in Karnataka and Andhra Pradesh

MedPlus Health Services has disclosed that its subsidiary, Optival Health Solutions Private Limited, received multiple suspension orders for drug licenses of stores situated in Karnataka and Andhra Pradesh. The regulatory actions, issued by the Drugs Control Administration, cite violations under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The company estimates a total potential revenue loss of ₹1.58 lakh due to these suspensions.

Regulatory Action Details

The subsidiary faced suspension orders from authorities in Hubli, Gadag, and Serilingampally. The orders involve suspensions ranging from one to three days for specific store locations. A recent update on June 30, 2026, detailed additional suspensions in the Gadag circle. The following table summarises the suspension orders and their associated financial impact:

Authority	Location	Suspension Duration	Potential Revenue Loss
Assistant Director, Drugs Control Administration, Hubli Circle, Hubli Karnataka	Adarsha Nagar Hubli, Karnataka	One day	₹0.22 lacs
Assistant Director, Drugs Control Administration, Gadag Circle, Gadag Karnataka	Rani Road Gadag, Karnataka	Two days	₹0.60 lacs
Assistant Director, Drugs Control Administration, Gadag Circle, Gadag Karnataka	Gajendragad and College Road Gadag, Karnataka	One day each	₹0.32 lacs and ₹0.47 lacs respectively
Assistant Director, Drugs Control Administration, Serilingampally Andhra Pradesh	Radhakrishna Nagar Attapur Andhra Pradesh	Three days	₹0.76 lacs

Key Highlights

Optival Health Solutions Private Limited is a subsidiary of MedPlus Health Services.
Suspension orders were received under Rule 65 of the Drugs and Cosmetics Act, 1940.
The orders impact stores in Hubli and Gadag in Karnataka, and Serilingampally in Andhra Pradesh.
The total quantifiable financial impact is a potential revenue loss of ₹1.58 lakh.

The disclosure was made to the BSE Limited and National Stock Exchange of India Limited on June 26, 2026, and June 30, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.25%	-0.89%	-7.09%	-2.93%	-11.19%	-27.85%

Optival Health Solutions Private Limited, a subsidiary of medplus health services , has received a suspension order for a Drug License from the Food and Drug Administration (FDA) Maharashtra. The order affects a store situated in Chowk, Saswad, Pune, and suspends operations for 10 days. The company estimates a potential revenue loss of ₹2.68 lacs due to this regulatory action.

The suspension was issued by the Assistant Commissioner & Licensing Authority, FDA Maharashtra, Pune. The order cites alleged violations under Rule 65 of the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The subsidiary received the order on June 20, 2026.

Details of the Regulatory Order

The following table outlines the specifics of the action taken by the regulatory authority:

Name(s) of the Authority	Nature and details of the action(s) taken	Date of receipt of direction or order	Details of the violation(s)/ contravention(s) committed	Impact on financial operation
Asst. Commissioner & Licensing authority, Food & Drug Administrations, MH, PUNE Mr. R.V.PONGALE	Suspension of Drug License for 10 days of store situated at Chowk Saswad Pune	Order received on 20.06.2026	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Potential Revenue Loss of Rs 2.68 lacs.

The disclosure was made pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was signed by Gangadi Madhukar Reddy, Managing Director and Chief Executive Officer of Medplus Health Services Limited.